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The emergence of resistance to antibiotics has been favored by abuse in the application
of antimicrobials in human and animal medicine. Essential oils are a great resource
to deal with this crisis. Melaleuca armillaris belongs to the family of Myrtaceae, rich
in species with essential oils. Plant extracts has shown antimicrobial activity in many
investigations. Cloxacillin (CLOX) is an antibiotic widely used in veterinary medicine
against Staphylococcus aureus. Our aim was to assess pharmacodynamic interaction
established by combining essential oil of M. armillaris (EO) with CLOX in search of a
synergistic effect that maximizes the antibacterial activity against S. aureus. The EO was
obtained by steam distillation and its composition was analyzed by a GC–FID–MS. The
most abundant components in the EO were 1.8 cineole (72.3%), limonene (7.8%). and
α-pinene (6%). We worked with wild type S. aureus strains (n = 3) isolated from Holstein
cows, and S. aureus ATCC 29213 as the reference strain. The Minimum Inhibitory
Concentration (MIC) of CLOX, EO and the combination was determined by microdilution
in broth at pH 7.4; 6.5 and 5.0. The checkerboard method was applied to evaluate
the interaction between CLOX and EO. The Fractional Inhibitory Concentration index
(FIC) was established. From those combinations that yielded the lowest FIC values, we
evaluated the index of antibacterial activity (E), established as the difference between the
Log10 values of the number of viable bacteria at the initial (nt0) and at the end of the test
(nt24). So, time-killing curves with CLOX and EO/CLOX combination at 0.5, 1, 2, 4, and 8
fold the MIC in broth at pH 7.4; 6.5 and 5.0 were prepared. We considered Bacteriostatic
effect (E = 0) Bactericidal effect (E = −3) and Effect of virtual eradication of bacteria
(E = −4). A clear synergic activity between the EO and the CLOX was demonstrated,
which allows reducing the MIC of β-lactam against S. aureus. This interaction was
favored by acidification of the medium, where lower concentrations of CLOX achieved a
bactericidal effect, close to virtual eradication, in the presence of small amounts of EO.
Keywords: Staphyloccocus aureus,Melaleuca armillaris, essential oil, cloxacillin, resistance, antimicrobial, MRSA,
synergism
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INTRODUCTION
Bovine mastitis is one of the most prevalent problem which
affects dairy herd production worldwide, and antimicrobial
therapy is the primary tool for the treatment. This disease
is responsible for a negative effect in the economy of several
countries, because of the decrease results in the production level
and quality of milk. The most frequent pathogen which caused
subclinical mastitis in dairy cows is Staphylococcus aureus (1).
This microorganism is characterized by its capacity of select
resistance against traditional antimicrobials and some virulence
factors as its ability to form biofilms and to invade and survive
inside epithelial cells (2).
The emergence of resistance to multiple antibiotics has been
favored by abuse in the application of antimicrobials in several
areas: medicine, veterinary, agriculture.
At present, the growing number of methicillin-resistant
S. aureus (MRSA) strains isolated from both groups, humans,
and animals, hazards the efficacy of traditional antimicrobial
treatments. The excessive and irrational usage of antimicrobials
favored the emergence of resistance to multiple antibiotic
families.
It is probably that the introduction of antimicrobials resistant
to β-lactamases in the 1960s led to the emergence ofMRSA (3). In
veterinary medicine literature, the isolation of MRSA in animals
has been reported since 1975 (4). This has been generating a
dissemination of resistant and multi-resistant strains transmitted
between humans and animals (5).
Cloxacillin (CLOX) is a semisynthetic antimicrobial derivate
of penicillin that resists being breakdown by the enzyme
penicillinase. CLOX is an antibiotic widely used in veterinary
medicine against S. aureus (1). It has bactericidal activity
against β-lactamase producing S. aureus.However, the increasing
occurrence of methicillin-resistance and the consequent failure
in therapy induces the search of new therapeutic alternatives.
An alternative to face the problem of bacterial resistance is
the use of products derived from plant extracts. In the past,
natural and phytochemical products were used in the treatment
and prevention of infectious diseases. Plants naturally synthesize
aromatic chemical compounds and secondary metabolites which
serve as a defense mechanism against microbes (6). The
biological activity of a medicinal plant is usually based on the
presence of one or a set of chemical components located in the
tissues of the plant. The compounds with antimicrobial activity
are mostly present in essential oils, which can occur in one or
more organs depending on the species (7). Essential oils turn out
to be the final product of the secondary metabolism of aromatic
plants (8).
Essential oils are an interesting kind of herbal extract
composed by complex mixtures with high antimicrobial
activities. It is useful to take advantage of this property and
transfer it to the treatment of bacteria resistant to antibiotics.
There are many works that establish the restoration of
antimicrobial activity of antibiotics, which have diminished their
Abbreviations: CLOX, Cloxacillin; EO, Melaleuca armillaris essential oil; MHB,
Mueller Hinton broth.
effectiveness against microorganisms, when they are combined
with essential oils (9–12).
The exploitation of essential oils in the prevention of bacterial
resistance is promising because those are multi-components
with different targets of action, compared to many conventional
antimicrobial agents that only have a single target site. Depending
on the composition of the essential oils, different mechanisms of
action can be attributed, including damage to essential proteins
of the pathogen, blocking of membrane enzymes with which the
microorganisms can pump out the active principle, changes in
the metabolism, permeabilization of their membranes. These oils
contain wide ranges of polyphenols and terpenoids, which have
strong binding affinity to different molecular structures such as
membranes, due to their great lipophilicity, presenting a high
potential to penetrate through cell walls and disorganize them,
leading to leakage cellular content (13).
Several authors are researching about the application of
essential oils as adjuvant to increase the effect of antimicrobials
against bacterial species. This is a new concept with high
potential. For example Pelargonium graveolens essential oil
reduces the minimum effective dose of norfloxacin against
Bacillus cereus, Bacillus subtilis, Escherechia coli, and S. aureus
(10). Rodrígues et al. (11) reported that the essential oil of leaves
of Croton zehntneri is able to enhance the activity of gentamicin
by 42.8% against Pseudomonas aeruginosa by gaseous contact,
which suggests that the oil has a potential to be used as an
adjuvant in antimicrobial therapy (11). Gram positive bacteria
as S. aureus are more susceptible to essential oils than Gram
negative ones (14), because these last one have an outer layer with
lipopolysaccharide that cover the peptidoglycan and limiting the
diffusion of hydrophobic compounds through it (15).
The antimicrobial properties of essential oils promote
scientific interest in the study of them as a new group of
pharmacological compounds. They possess a huge chemical and
structural variety, converting them into functionally versatile
mixtures (9). Although their activity can be associated with the
major components, all of them influence in the pharmacological
effect. It is probably that the high concentration of the major
compounds masks the effects of the others. However, in terms
of antimicrobial activity, every isolated component shows less
antibacterial effect than the complete essential oil (16). It has
also been shown that the function of the main compounds is
regulated by the minority molecules, contributing to the synergic
effect (17). Considering the large number of chemical structures
that make up the essential oils it is likely that antibacterial
properties cannot be attributed to a single chemical compound,
and therefore there could be several targets in the microbial cells
where these would act resulting in an enhancing influence. That
is why it is reasonable to study the essential oils as a whole and
take advantage of the synergy of all the components (18).
Melaleuca armillaris (Soland. ex Gaertn.) Sm. is one of
the most widely cultivated Melaleuca plants. It is commonly
known as Honey Bracelet Myrtle and grows in the form of a
large bush or as a small tree. Reports of the literature about
M. armillaris essential oil (EO) remain scarce. Investigations
by GC-MS of its EO revealed the presence of 1.8-cineole as
the major component (19–21). Several activities have been
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determined for this EO. Rizk et al. (22) obtained positive
results in vivo using this EO in the treatment against the
parasitoid Schistosoma mansoni, responding to the oxidant
activity generated by the pathogen. Inhibitory activity was also
found, in vitro, against some bacterial species such as B. subtilis,
S. aureus, S. epidermidis, E. coli, and P. aeruginosa (22, 23). The
activities observed for the EO of M. armillaris in pure form
allow supposing that the good results obtained by themselves
can be increased in synergistic systems for the same purpose,
such as the improvement of antibiotics to treat infections caused
by strains resistant to conventional treatment. No bibliography
has been found indicating the use of the essential oil of
M. armillaris as an enhancer of antibiotics used in the treatment
of microbial infections, particularly against strains of S. aureus.
This pathogen is very resistant to antibiotics, and is responsible
for high percentage persistent infections. The indiscriminate
use of antimicrobials is generating microorganisms resistant to
multiple drugs, becoming a serious problem for global health
(24).
Our aim was to assess the pharmacodynamic interaction
established by combining EO of M. armillaris with CLOX
emulating an extracellular and intracellular pH conditions (pH
7.4, 6.5, and pH 5) in search of a synergistic effect that maximizes
the activity of the antibiotic against S. aureus.
MATERIALS AND METHODS
Plant Material and Essential Oil Extraction
Leaves and herbaceous branches of M. armillaris were collected
in the month of July in the outskirts of Coronel Brandsen town,
near La Plata city, Buenos Aires, Argentina. This region is located
at latitude 35◦06′18.9′′S and longitude 58◦10′57.0′′W, and the
climate is warm and humid with very rainy winters. The plant
material was deposited in the LPAG Herbarium of the Faculty of
Agrarian and Forestry Sciences, UNLP (25).
Vegetal material collection and extraction of the EO were
carried out in the month of July during the morning. The
extraction of EO was done by steam distillation with a distillation
equipment of 385 liters of capacity. We used 38.5 liters of water
for steam distillation and the amount of leaves and herbaceous
branches was 44.750 kg. The EO obtain was dried with anhydrous
Sodium Chloride, filtered and stored in amber glass bottle in a
refrigerator at 4◦C until use.
Analysis of Composition
The EO was analyzed by a GC–FID–MS Agilent (Agilent
Technologies, Santa Clara, CA, USA) 7890A/5975C, equipped
with one injector (split ratio 1:100), connected by a flow
splitter to two capillary columns (HPWAX and DB-1-MS, both
60m × 0.25mm with 0.25µm of fixed phase). The polar
column was connected to a FID, whereas the non-polar column
was connected to a quadrupolar mass detector (HP 5975C;
70 eV). Helium was used as gas carrier, at 1.8 mL/min. The
injector temperature was set at 250◦C. Injection volume was
0.3 µL. The column temperature was programmed according
to the following gradient: 100◦C, increasing at 2◦C/min to
240◦C and kept constant for 15min. FID temperature was
260◦C, and temperatures for the transference line and the
ionic source were set at 280 and 230◦C, respectively. Mass
range (m/z) was 40–500 Da. Data acquisition, processing
and instrument control was performed using the Agilent
ChemStation (Agilent Technologies, Santa Clara, CA, USA)
software. The identification of the compounds was achieved
by analyzing the retention indexes (relative to C8–C24 n-
alkanes) obtained in both columns and compared with those
of reference compounds identified in chemically well-known
essential oils and from bibliography (26, 27). Additionally,
each mass spectra obtained was compared to those from the
literature libraries (26, 28, 29) and mass spectra obtained
from reference compounds. Relative percentage contribution of
the compounds was calculated from the FID response by a
computerized integration assuming all of the responses factors
were 1.
Microorganism and Antibiotic
The study was carried out using 3 wild strains of S. aureus
and the S. aureus ATCC 29213 as reference strain for quality
control. Wild strains were isolated from milk samples obtained
of Holstein cows with subclinical mastitis. They were identified
by colonymorphology and routine biochemical tests, Gram stain,
coagulase, and catalase test, development of β-hemolysis, glucose
fermentation and growth in saline medium (7.5%).
A standard of CLOX, pontency 96.4% (Sigma-Aldrich,
chemical Company, St. Louis, USA) was used to performed this
assay.
TABLE 1 | Percent composition of M. armillaris essential oil (EO).
Compound No polar Polar Area percentage
α-Tujene 926 1036 1.5
α-Pinene 935 1043 6.0
Sabinen 968 1138 1.0
Myrcene 974 1170 2.2
β-Pinene 979 1133 2.2
α-Phellandrene 1005 1191 0.1
α-Terpinene 1012 1206 0.2
P-Cimene 1018 1286 1.4
1.8-Cineole 1022 1234 72.3
Limonene 1024 1221 7.8
Trans-β-Ocimene 1032 1260 0.2
γ-Terpinene 1047 1264 0.5
Terpinolene 1082 1305 0.1
δ-Terpineol 1150 1674 0.1
Terpinen-4-ol 1164 1614 1.4
α-Terpineol 1172 1705 1.4
Geranyl acetate 1359 1760 0.2
β-Caryophyllene 1417 1614 0.5
Aromandendrene 1437 1622 0.1
Geranyl isobutyrate 1496 1794 0.1
Cis-Calamenene 1508 1841 0.1
Oxi-Caryophyllene 1565 1989 0.1
Frontiers in Veterinary Science | www.frontiersin.org 3 August 2018 | Volume 5 | Article 177
Buldain et al. M.armillaris EO Against S. aureus
Minimum Inhibitory Concentration (MIC) of
CLOX and EO of M. armillaris
To determine the MIC of CLOX and EO, we used 96-well
polystyrene microtiter plates with Mueller Hinton broth (MHB)
supplemented with 0.5% of Tween 80 (to enhance the EO
dissolution). The broth was adjusted to pH 7.4, 6.5, or 5.0 with
hydrochloric acid 1N (Anedra, Argentina), in order to emulate
the conditions of pH to extracellular and intracellular level. The
range of CLOX concentrations (applying a scheme of two-fold
serial dilution) evaluated was from 256 to 0.007µg/mL. The
concentrations of EO tested were from 50 µL/mL to 0.1 µL/mL.
In both cases each well was inoculated with a final bacterial
concentration of 5 × 105 CFU/mL. The suspension was adjusted
to match 0.5 Mc Farland (1 × 108 CFU/mL). The plates were
incubated at 35◦C for 18–24 h. The MIC was established as the
lowest concentration which inhibits the bacterial growth. All
determinations were carried out in triplicate and in all cases
positive and negative controls were used with MHB containing
0.5% Tween 80.
Minimum Inhibitory Concentration (MIC) of
CLOX/M. armillaris EO Combination
The MIC of the mixture was performed as previously described
by CLOX and EO. The combinations of the antibiotic and
the plant extract were prepared according to checkerboard
technique (30) against the strains selected. The microtiter plate
consisted of a row with two-fold serial dilution of EO and a
column with two-fold serial dilution of CLOX (as MIC control).
The intermediate wells presented EO/CLOX combinations. The
results were interpreted as for MIC of individual antimicrobials,
but considering this parameter as a mix. The bacterial inoculums
of S. aureus wild type and the reference strain used was 5 ×
105 CFU/mL per well. Incubation was carried out at 35◦C for
18–24 h. The fractional inhibitory concentration index (FIC) was
determined according to the following equation:
(A)
(MIC)a
+
(B)
(MIC)b
= FIC
Where (A): CLOX MIC in combination with EO; (B): EO MIC
in combination with CLOX; (MIC)a and (MIC)b: MIC of the
antimicrobial and EO alone, respectively. Synergism (S) was
considered if FIC≤ 0.5; partial or low synergism (PS) if 0.5< FIC
<1; indifference or addition (I) if 1≤ FIC<2 and antagonism (A)
when FIC ≥ 2.
TABLE 2 | Cloxacillin MIC values obtained for the 4 strains at pH 7.4; 6.5 and 5.0.
Strain MIC pH 7.4µg/mL MIC pH 6.5µg/mL MIC pH 5.0µg/mL
ATCC 29213 0.125 0.062 0.031
SA 13 0.5 0.125 0.031
SA 96 0.5 0.125 0.031
SA 139 0.5 0.125 0.031
TABLE 3 | MIC values of the EO at pH 7.4; 6.5 and 5.0.
Strain MIC pH 7.4µL /mL MIC pH 6.5µL /mL MIC pH 5.0µL /mL
ATCC 29213 25 25 12.5
SA 13 12.5 12.5 6.25
SA 96 12.5 12.5 6.25
SA 139 12.5 12.5 6.25
FIGURE 1 | Mass spectra of all fractions Melaleuca armillaris pure essential oil by GC-FID-MS assay.
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Time-Killing Curves and Antibacterial
Activity Index of the AE/CLOX Combination
The antibacterial activity index (E) was evaluated from those
combinations that showed the lowest FIC values, established
as the MIC value of the mixture. For this purpose we carried
out time-kill assays for different concentrations (0.5MIC; 1MIC;
2MIC; 4MIC; 8MIC) of EO, CLOX and the combination. For the
last one, 1MIC correspond to the lower FIC value blending and
the others (0.5MIC, 2MIC, 4MIC, 8MIC) keep the proportion
of both compounds (diluting or concentrating as the case may
be). We prepared 7 tubes in each case (considering control
positive and negative) with 1mL of final volume containing
MHB 0.5 Tween 80, antimicrobial (or AE/CLOX combination)
and the inoculums. All tubes had a bacterial concentration of
approximately 5 × 105 CFU/mL (except the negative control).
They were incubated at 35◦C and samples were obtained at 0,
2, 4, 8, 12, and 24 h in order to construct survival curves by plate
count. Those were performed for all strains at pH 7.4; 6.5 and 5.0.
The E index was quantified as the difference between the Log10
values of the number of viable bacteria (CFU/mL) at initial time
(nt-0) and at the end of the test (nt-24) according to the following
equation: E = nt-24-nt-0. To evaluate E, three theoretical cut
points were applied (31): (a) Bacteriostatic effect: E = 0; there
are no changes in the value of nt-0; (b) Bactericidal effect: E =
−3; there is a reduction of ≥3 log10 of nt-0 and (c) Effect of
virtual eradication of bacteria: E = −4; there is a reduction of
≥4 Log10 (99.99%) respect to Log of nt-0. The results obtained
were plotted using the GraphPad Prism 6 program in order to
obtain E vs. Log10 (concentration of CLOX) curves. The assays
were performed in triplicate and the wild strains were grouped
obtaining an n= 3.
RESULTS
The whole distillation process lasted 5 h and 550mL of essential
oil were extracted. The analysis of composition revealed the
presence of 1.8 cineole (72.3%), limonene (7.8%) and α-pinene
(6%) as the most abundant components in the EO (Table 1,
Figure 1).
The strains used in this study were identified as members
of S. aureus specie after characterizing them biochemically,
resulting in Gram positive, coagulase positive, catalase positive,
β-hemolytic, glucose fermenting, and growth in saline (7.5%)
strains.
The MIC of the CLOX obtained for S. aureus ATCC 29213
at pH 7.4 was 0.125µg/mL, which is in accordance with the
recommendations of the CLSI 2009 (32). The 3 wild strains
(named SA13, SA96, and SA139) presented a MIC of 0.5µg/mL
at pH 7.4. In all cases, a decrease in this concentration was
observed when acidifying the culture medium (Table 2).
Respect the M. armillaris EO, for S. aureus ATCC 29213 the
MIC was 25 µL/mL, while for the 3 wild strains it was 12.5
µL/mL. These values decreased slightly with the acidity of the
culture medium (Table 3).
With the evaluation of the antibacterial activity index we could
compare the incidence of EO in the CLOX activity, in addition
FIGURE 2 | Graphic representation of the antibacterial effect (E: 1 Log CFU/mL 24–0 h) of Cloxacillin against S. aureus ATCC 29213 (n = 3) at pH 7.4 (A); 6.5 (B)
and 5.0 (C) in the presence and absence of EO.
FIGURE 3 | Graphic representation of the antibacterial effect (E: 1 Log CFU/mL 24–0 h) of Cloxacillin against WILD S. aureus strains (n = 3) at pH 7.4 (A); 6.5 (B) and
5.0 (C) in the presence and absence of EO.
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to the effect caused by the pH variation. This is visualized in
Figures 2, 3. It is observed how the acidification of the medium
enhances the antimicrobial activity of CLOX against S. aureus
(for the reference strain and the wild strains). Lower pH values
requires a less amount of antibiotic to obtain an E-value lesser
than −3 indicating a bactericidal effect. In the graphs it can be
seen how the presence of the EO favors the action of the CLOX,
since lower E-values are reached with lower concentrations of
the antibiotic in comparison with the results obtained for CLOX
alone. For the reference strain ATCC 29213, it was achieved a
bactericidal effect very close to virtual eradication, since the E-
values are close to −4. This was observed from concentrations
of 2 the MIC of CLOX in the mixture, at the 3 pHs evaluated
(Figure 2). In wild isolates the behavior was similar to that
observed for the reference strain (Figure 3).
DISCUSSION
The chromatographic analysis of our EO revealed the presence of
1.8 cineole as major component (72.3%) and in lesser magnitude
limonene (7.8%) and α-pinene (6.0%). Those are commonly
present in effective antimicrobial essential oils. The 1.8 cineole
is a monocyclic monoterpene with high antimicrobial activity.
In several studies (19, 22, 33, 34), the main component reported
was also 1.8 cineole, but this result disagree with other authors
like Amri et al. (23) because the concentration of this one was
markedly low (3.6%). There is evidence that the differences found
in the concentration of the components in essential oils, extracted
from different plants, would be affected by environmental
conditions (35). The main compound of the mixture generally
exerts the strongest activity, but can be influenced by the other
molecules (36).
In our study, EO alone, without the addition of the
antimicrobial, have demonstrated a strong antibacterial activity
against S. aureus, this result agree with the research carried out
by Amri et al. (23). The MIC against S. aureus ATCC 29213 was
25 µL/mL at pH 7.4 and it decreased 2-fold at pH 5. This result
was also observed in wild strains.
A clear synergic effect was observed for the combination
EO/CLOX, since FIC values obtained were ≤1 (Table 4). When
we faced the EO/CLOX combination against the S. aureus
strains, there was a great decreased in the concentration of
antibiotic necessary to inhibit the bacterial growth. In EO/CLOX
combination the bactericidal effect was maintained even when
the pH of the broth was reduced from 7.4 to 5.0, as we have
mentioned above when EO was studied without CLOX. And
in the same way, when the culture medium was acidified, the
concentration of CLOX, in the mixture EO/CLOX, was reduced
even up to 10-fold to inhibit the microorganism. As we have
mentioned in the introduction, there is still no published works
where the pharmacological interaction between theM. armillaris
EO and CLOX has been studied. In the bibliography another
Melaleuca sp., M. alternifolia (tree of tea), has been widely
investigated using the checkerboard technique against S. aureus.
However, the results obtained when combining its EO with
different antibiotics such as vancomycin (37), tobramycin (38),
and ciprofloxacin (39) were indifference or antagonism effect.
The combined activity of EO and CLOX, used in our study,
was also evidenced in the bactericidal effect, established by
the E index. The decrease in the initial bacterial inoculum -
Log10 (CFU/mL)- in a factor of 3 in 24 h marked bactericidal
activity observed in both for the CLOX alone and for the
mixture. However, the concentration of the antimicrobial
in the presence of EO was clearly lower and the E-
value obtained was closer to the virtual eradication effect
(E = −4) than the concentration needed when applying β-
lactam alone. In a study conducted by Nascimento et al. (40)
the essential oil of Eremanthus erythropappus was evaluated
in combination with ampicillin (β-lactam antibiotic) against
S. aureus achieving a synergistic bactericidal effect after 24-h
incubation (40).
In conclusion, it was possible to reduce the concentration of
the antibiotic needed to inhibit S. aureus by combining CLOX
with EO in vitro. Considering that CLOX is an antimicrobial
of the group of β-lactams with good activity against S. aureus
and with wide use in veterinary medicine, the EO enhance
CLOX antibacterial effect even when the intracellular pH were
more acid than the extracellular medium. This is important
for the treatment of intracellular infections where S. aureus is
internalized inside of phagolysosomes because the probability of
therapeutic success would be really increased. Our results suggest
an increase of the susceptibility to β-lactams due to the acidic
pH prevailing in the vacuoles where S. aureus live and prosper,
which would be facilitated by the action ofM. armillaris EO. The
acid pH causes a conformational change of the target protein
of action (PBP2a), increasing the affinity of its catalytic center
for β-lactam (41). So the synergy we found between CLOX and
EO in acid conditions could take place in the inner cell and
have an important effect against S. aureus when it is refractory
to immunological mechanisms. These findings become into a
TABLE 4 | Fractional concentration indexes (FIC) obtained for the EO/CLOX combination under different pH conditions vs. individual MICs.
Strain pH 7.4 pH 6.5 pH 5.0
MIC EO
µL/mL
MIC
CLOX
µg/mL
MIC
EO/CLOX
(µL/mL)/(µg/mL)
P
FIC MIC EO
µL/mL
MIC
CLOX
µg/mL
MIC
EO/CLOX
(µL/mL)/(µg/mL)
P
FIC MIC EO
µL/mL
MIC
CLOX
µg/mL
MIC
EO/CLOX
(µL/mL)/(µg/mL)
P
FIC
ATCC 29213 25 0.125 25/0.031 0.75 25 0.062 0.62/0.007 0.36 12.5 0.031 3.1/0.0035 0.36
13 12.5 0.5 6.25/0.125 0.62 12.5 0.125 12.5/0.015 1.12 6.25 0.031 3.1/0.0035 0.61
139 12.5 0.5 6.25/0.125 0.62 12.5 0.125 12.5/0.015 1.12 6.25 0.031 3.1/0.0035 0.61
96 12.5 0.5 6.25/0.125 0.62 12.5 0.125 12.5/0.015 1.12 6.25 0.031 3.1/0.0035 0.61
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valuable alternative for the treatment of persistent staphylococcal
infections.M. armillaris EO needs to be considered in the design
of future formulations to evaluate in vivo effects, in order to
maximize the efficacy of current and future antimicrobials.
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